RenovoRx Files Q1 2025 10-Q
Ticker: RNXT · Form: 10-Q · Filed: May 15, 2025 · CIK: 1574094
| Field | Detail |
|---|---|
| Company | Renovorx, INC. (RNXT) |
| Form Type | 10-Q |
| Filed Date | May 15, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financials, pharmaceuticals
TL;DR
**RenovoRx Q1 2025 10-Q filed. Shows stock, capital, and other comprehensive income data.**
AI Summary
RenovoRx, Inc. filed its 10-Q for the period ending March 31, 2025. The company, focused on pharmaceutical preparations, reported financial data for the first quarter of 2025. Key financial statement items like preferred stock, common stock, additional paid-in capital, and accumulated other comprehensive income were detailed for the periods ending March 31, 2025, December 31, 2024, and December 31, 2023.
Why It Matters
This filing provides investors with the latest financial snapshot of RenovoRx, Inc., detailing their capital structure and financial health as of the end of the first quarter of 2025.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, RenovoRx faces inherent risks related to drug development, regulatory approvals, and market competition, which are not detailed in this specific filing but are typical for the sector.
Key Numbers
- Q1 2025 — Reporting Period (Financials for the first quarter of 2025 are presented.)
- 2024-12-31 — Previous Year End (Comparative financial data from the end of 2024 is included.)
- 2023-12-31 — Prior Year End (Comparative financial data from the end of 2023 is included.)
Key Players & Entities
- RenovoRx, Inc. (company) — Filer of the 10-Q
- 20250331 (date) — End of the reporting period
- 20250515 (date) — Filing date
- 2834 (industry_code) — Standard Industrial Classification for Pharmaceutical Preparations
FAQ
What is the primary business of RenovoRx, Inc.?
RenovoRx, Inc. is primarily involved in Pharmaceutical Preparations, as indicated by its Standard Industrial Classification code 2834.
What is the reporting period for this 10-Q filing?
The reporting period for this 10-Q filing is the quarter ended March 31, 2025.
When was this 10-Q filed with the SEC?
This 10-Q was filed on May 15, 2025.
What specific financial statement components are detailed in the filing for the reporting period?
The filing details components such as Preferred Stock, Common Stock, Additional Paid-In Capital, and Accumulated Other Comprehensive Income for the period from January 1, 2025, to March 31, 2025.
What is the company's principal business address?
The company's business address is 2570 W. El Camino Real, Ste. 320, Mountain View, CA 94040.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 15, 2025 regarding RenovoRx, Inc. (RNXT).